



An important function of Nrf2 in combating oxidative stress: Detoxification of acetaminophen

Kaimin Chan*, Xiao-Dong Han*, and Yuet Wai Kan**†

*Cardiovascular Research Institute, †Department of Laboratory Medicine and Howard Hughes Medical Institute, University of California, San Francisco, CA 94143-0793

Contributed by Yuet Wai Kan, February 20, 2001

Nrf2, a member of the “cap ‘n collar” group of transcription factors, is important for protecting cells against oxidative damage. We investigated its role in the detoxification of acetaminophen [N-acetyl-*p*-aminophenol (APAP)]-induced hepatotoxicity. When Nrf2 knockout (Nrf2^{-/-}) and wild-type mice were given APAP by i.p. injection, the Nrf2^{-/-} mice were highly susceptible to APAP treatment. With doses of APAP that were tolerated by wild-type mice, the Nrf2^{-/-} mice died of liver failure. When hepatic glutathione was depleted after a dose of 400 mg/kg of APAP, the wild-type mice were able to compensate and regain the normal glutathione level. In contrast, the glutathione level in the Nrf2^{-/-} mice was not compensated and remained low. This was because of the decrease in the gene expression of *gcsH* and *gcsL* as well as *gss* in the livers of the Nrf2^{-/-} mice. In addition, the expression of *ugt1a6* and *gstpi* that detoxify APAP by conjugation was also decreased. This increased susceptibility of the Nrf2^{-/-} mice to APAP, because of an impaired capacity to replenish their glutathione stores, compounded with a decreased detoxification capability, highlights the importance of Nrf2 in the regulation of glutathione synthesis and cellular detoxification processes.

CNC transcription factor | gene knockout | antioxidant response element | γ -glutamylcysteine synthetase

The transcription factor Nrf2 is a member of the “cap ‘n collar” family of basic leucine zipper transcription factors. The family is made up of six members: p45-Nfe2, Nrf1, Nrf2, Nrf3, Bach1, and Bach2 (1–7). The first three were originally cloned during the search for proteins that bind to the NFE2-AP1 motif, the core element on hypersensitive site 2 of the locus control region of the human β -globin gene cluster (8–10).

The NFE2-AP1 motif was later determined to share high sequence homology to the antioxidant response element (11–14), and Nrf1 and Nrf2 were shown to play important roles in the cellular detoxification process by several lines of evidence. Nrf1 and Nrf2 transactivate reporter genes linked to antioxidant response elements, and their sites of expression coincide with those of many of the phase II detoxifying genes (15–17). Nrf2 mediates the induction of detoxifying genes, NAD(P)H quinone oxidoreductase 1 and glutathione *S*-transferases (GSTs), by the phenolic antioxidant butylated hydroxyanisole (18). Nrf2 was also found to be essential for the protection against butylated hydroxytoluene-induced pulmonary injury (19). Nrf2 regulates the expression of other detoxifying genes such as heme oxygenase 1 (20), catalase, superoxide dismutase 1, UDP-glucuronosyltransferase [(UGT)1a6], and γ -glutamylcysteine synthetase (GCS), as evidenced by a lower expression of these genes in the Nrf2^{-/-} mice (19). In addition, the regulation of GCS, the rate-limiting enzyme in the synthetic pathway of glutathione (GSH), by Nrf2 was recently demonstrated in Nrf2^{-/-} fibroblasts, hepatocytes, and HepG2 cells (21–23).

Acetaminophen [N-acetyl-*p*-aminophenol (APAP)] is one of the most widely used analgesic and antipyretic drugs worldwide, and as such, its biochemical properties has been extensively studied (24). It is marketed under different brand names and is also incorporated in formulation with other

drugs. It is generally considered a safe drug at normal therapeutic dose levels but is a major cause of liver failure and causes death when taken in excess. Under normal conditions, APAP is primarily metabolized in the liver by glucuronidation catalyzed by UGTs and sulfation by sulfotransferases. A small amount of the drug is metabolized by several of the cytochrome p450 enzymes into the reactive intermediate *N*-acetyl-*p*-benzoquinoneimine (NAPQI), which is normally detoxified by GSH both nonenzymatically and enzymatically in a reaction catalyzed by GSTs. In overdose, sulfation and glucuronidation become saturated, and GSH is depleted by NAPQI. Excess NAPQI causes oxidative stress and binds covalently to liver proteins. Although the precise mechanism by which APAP or its metabolites cause cell injury is still unknown, cell death and organ failure most likely result from the cumulative and additive effects from oxidative damage, depressed mitochondrial functions, and disruptions of calcium homeostasis and redox balances (24).

In light of the role of Nrf2 in the regulation of expression of GCS, GSTs, and UGT1a6, we used Nrf2^{-/-} mice to investigate whether lack of this transcription factor renders the mice more vulnerable to APAP poisoning. We report here that i.p. injection of APAP at doses well tolerated by wild-type mice results in a high mortality rate in Nrf2^{-/-} mice, and that the *de novo* synthesis of hepatic GSH, on depletion by APAP, is impeded because of down-regulation of GCS and glutathione synthetase (GSS) in Nrf2^{-/-} mice.

Materials and Methods

Chemicals. APAP and *N*-acetylcysteine (NAC) were purchased from Sigma. APAP was dissolved in warm buffered saline at concentrations of 10–40 mg/ml and delivered at doses ranging from 100 mg/kg to 800 mg/kg by injecting 0.1–0.20 ml per 10 g of body weight. NAC was dissolved in sterile saline (pH adjusted to 7.4) at a concentration of 1,200 mg/ml and delivered at doses of 1,200 mg/kg by injecting 0.1 ml per 10 g body weight.

Animals. Wild-type and Nrf2^{-/-} mice were obtained by breeding from our stock of C57/SV129 mice. Adult male and female mice (10–15 weeks old) were used for this study.

Survival and Hepatotoxicity Studies. For survival studies, 8 each of wild-type or Nrf2^{-/-} male or female mice were given 100–800 mg/kg APAP i.p. and observed for survival for 48 h. To evaluate hepatotoxicity, female wild-type and Nrf2^{-/-} mice were given APAP i.p. at 100, 200, and 300 mg/kg body weight with 10 mice per dose. Blood was collected by retroorbital

Abbreviations: GST, glutathione *S*-transferase; GCS, γ -glutamylcysteine synthetase; GSH, glutathione; APAP, *N*-acetyl-*p*-aminophenol; UGT, UDP-glucuronosyltransferase; NAC, *N*-acetylcysteine; ALT, alanine aminotransferase; SF, Sigma-Frankel; GSS, glutathione synthetase.

*To whom reprint requests should be addressed. E-mail: kanyuet@labmed2.ucsf.edu.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Table 1. Primers for amplification of cDNA fragments used for probes

Gene	Sense primer	Antisense primer
GCS _H	ACAAGCACCCCGCTTCGG	CTCCAGGCCTCTCTCCTC
GCS _L	ATGTTTGGAAATGCACCATGTCC	TGAGCTGGAGTTAAGAGCCC
GSS	GCGGTGGTCTACTGATTGC	CACTGGACCACTTGGGCAGG
GST pi	TTTGGGGCTTTATGGGAAA	ACATAGGCAGAGAGCAGGGG
UGT1a6	CTTCCTGCAGGGTTCTCTTCC	CAACGATGCCATGCTCCCC
GAPDH	CAGTGCCAGCCTCGTCCC	CCAAGATGCCCTTCAGTGGG

bleeding at 24 h for measurement of the serum alanine aminotransferase (ALT). To test the mechanism of toxicity, female mice were given one dose of NAC (an antidote to APAP poisoning) 1,200 mg/kg body weight, together with APAP at 300, 400 or 600, and 800 mg/kg body weight with 8 mice per dose of APAP. Blood was collected at 24 h for serum ALT measurement. To measure GSH level and gene expression, 9 female mice of each genotype were injected with 100 or 400 mg/kg APAP, and 3 mice were killed at 90, 180, and 270 min after injection to collect blood for ALT measurements and liver tissues for histology, GSH assays, and gene expression studies. Serum ALT activities, expressed in Sigma–Frankel (SF) units per milliliter, were assayed in duplicate by using a kit (Sigma), and samples were diluted in sterile saline when values obtained were above the maximum threshold detectable by the kit, as recommended by the manufacturer.

Histology and Northern Blots. Mice were killed by cervical dislocation, and the liver was collected and rinsed in PBS. One lobe of the liver was fixed in buffered formalin solution and paraffin embedded. Sections (7 μ m) were stained with hematoxylin and eosin. One small piece of the liver was flash frozen in a preweighted tube by immersing into liquid nitrogen. GSH levels in livers were measured by using a total GSH kit from Oxis International (Portland, OR). Briefly, the piece of frozen liver was homogenized in 20 \times volume to weight of 7.5% trichloroacetic acid, the homogenate cleared by centrifugation, and 100 μ l of cleared lysate was assayed according to the manufacturer's protocol. The rest of the liver was stored in RNAlater (Ambion, Austin, TX) for RNA extraction. Northern blots were performed according to standard procedures. Total RNA was extracted from liver by using Ultraspec RNA (Bio-Tex, Edmond, AL, Canada). The radioactivities of the Northern blots were quantified with Fuji imaging plates and an FLA-2000 image analyzer (Fuji). The activities of the Nrf2^{-/-} bands, and wild-type bands were normalized with those of the glyceraldehyde-3-phosphate dehydrogenase bands. Gene expression was calculated relative to values for the untreated wild-type mice expressed as 100%.

Probes Used in Gene Expression Studies. Primer pairs were designed from sequences from GenBank. First-strand cDNAs were reverse transcribed from total RNA with random hexamers by using Omniscript from Qiagen (Chatsworth, CA). The sequences of primers used to amplify the cDNAs are shown in Table 1. The amplified cDNA fragments were then subcloned and sequenced to confirm their identities.

Results

Survival of Mice with APAP Challenge. APAP treatment by i.p. injection generated dose-response curves that were genotype and gender dependent. Nrf2^{-/-} mice were more susceptible than wild-type mice, and male mice of either genotype were more susceptible than their female counterparts (Fig. 1). Furthermore, the Nrf2^{-/-} mice died rapidly between 6 and




Fig. 1. Survival of Nrf2^{-/-} and wild-type mice injected i.p. with increasing doses of APAP. Percent survival at 48 h is plotted as a function of dose. LD₅₀ values are indicated with arrows. Eight mice were used for each dose.

12 h after injection, whereas the wild-type mice died over a more extended period, with the last deaths occurring between 36 and 48 h. The LD₅₀ was 235 and 320 mg/kg for male and female Nrf2^{-/-} mice, respectively, and 400 and 540 mg/kg for the male and female wild-type mice, respectively. Starting with a cohort of 8 animals per dose, 1 male wild-type animal survived dosages of 500 or 600 mg/kg, and 1 female wild-type animal overcame a dosage of 600 mg/kg. A dosage of 700 mg/kg or higher resulted in 100% mortality for both sexes of wild-type animals.

Serum ALT Level. In this experiment, only female mice were used. Baseline serum ALT activities in untreated mice of either genotype ranged between 13 and 48 SF units/ml. APAP treatment at the dose of 100 mg/kg body weight did not elevate serum ALT activities in the wild-type mice. Nrf2^{-/-} mice exposed to the same dose showed a wide variation in serum ALT activities that ranged from 27 to 4,200 SF units/ml. At doses of 200 and 300 mg/kg of APAP, both Nrf2^{-/-} and wild-type mice exhibited a wide range of ALT levels from 33 to 13,000 SF units/ml and 25 to 8,400 SF units/ml, respectively (Fig. 2A). Because of the large spread of values, there were no significant statistical differences in serum ALT activities between the genotypes ($P_{(100)} = 0.056$, $P_{(200)} = 0.102$, $P_{(300)}$ not calculated). However, at 300 mg/kg APAP, two Nrf2^{-/-} mice died before 24 h, and two others died at 48 h, whereas no death occurred in the wild-type controls.

Rescue from APAP Toxicity by NAC. NAC, the commonly used antidote to APAP poisoning, was coadministered with different doses of APAP. A single dose of NAC at 1,200 mg/kg body weight i.p. abrogated the elevation of serum ALT activities seen when 300 mg/kg dose of APAP was injected by itself in animals of both genotypes (Fig. 2B). When LD₁₀₀ of APAP were used, NAC rescued 100% of the wild-type mice treated with a 600 mg/kg dose of APAP, lowering the measured serum ALT levels to between 31 and 195 SF units/ml, comparable to the level obtained in untreated controls. NAC partially alleviated the toxicity of APAP in the Nrf2^{-/-} mice treated with the LD₁₀₀ dose of 400 mg/kg, as only 2 of the 8 Nrf2^{-/-} mice treated with NAC died. The serum ALT of the




Fig. 2. Individual serum ALT values of mice at 24 h after injection with different doses of APAP. (A) Ten wild-type (WT) and *nrf2* knockout (KO) mice were injected with doses of 100, 200, and 300 mg/kg APAP; individual serum ALT values are plotted ($P_{(100)} = 0.056$, $P_{(200)} = 0.102$; $P_{(300)}$ was not calculated because two data points were lost when two *Nrf2*^{-/-} mice died before blood collection). (B) Eight wild-type and *nrf2* knockout mice were injected with 1,200 mg/kg NAC (+N) in addition to APAP at 300, 400 or 600, and 800 mg/kg APAP.

surviving mice ranged between 110 and 1,440 SF units/ml, higher than the levels obtained from the wild-type mice treated with NAC and 600 mg/kg APAP, none of which died (Fig. 2B). When treated with 800 mg/kg APAP, a dose that killed 100% of mice of either genotype, wild-type mice benefited most from NAC antidote, and serum ALT values at 24 h ranged from 31 to 3,900 SF units/ml. The one wild-type animal with the highest ALT level of 3,900 SF units/ml died between 36 and 48 h. NAC treatment did not protect the *Nrf2*^{-/-} mice as effectively as the wild-type mice. At this dose of APAP and NAC, only 2 of the *Nrf2*^{-/-} mice (25%) survived beyond 24 h, and only 1 single animal (12.5%) survived beyond 48 h. The 48-h survival of mice of either genotype treated with APAP with or without NAC is presented in Table 2.

GSH Levels. For the measurement of GSH levels and the expression of genes involved in synthesis of GSH and detoxification of APAP metabolites, we used one nonlethal and one lethal dose to maximize the difference in the response to APAP between wild-type and *Nrf2*^{-/-} mice. Three time points at 90-min intervals were chosen because *Nrf2*^{-/-} mice were observed to begin dying by 5.5–6 h after injection. APAP at 100 mg/kg body weight

caused only a slight drop in the GSH levels of the wild-type mice but caused a larger drop in the *Nrf2*^{-/-} mice at 90 min (Fig. 3A). At 180 min, in both genotypes, the GSH contents were back to baseline level and surpassed the baseline level at 270 min. The ALT activities for these mice were all within normal limits (data not shown).

A dose of 400 mg/kg of APAP caused a precipitous drop of the GSH levels in both genotypes at 90 min to 5 and 4% of the untreated levels for wild-type and *Nrf2*^{-/-} mice, respectively. In the wild-type mice, the GSH levels recovered to 35% of baseline at 180 min and 74% at 270 min, but in the *Nrf2*^{-/-} mice, the GSH levels remained low, at 6 and 8% of baseline, respectively (Fig. 3A). The ALT activities for all these mice at 90 and 180 min were within those of the untreated mice. The ALT activities at 270 min were elevated to 600, 3,000, and 8,800 SF units/ml for the *Nrf2*^{-/-} mice, and 160, 210, and 2,300 SF units/ml for the wild-type mice.

Gene Expressions. Northern blot analysis of liver RNAs revealed that the genes for both the light and heavy chain subunits of GCS_H and GCS_L were expressed at 58 and 65% of wild-type control, respectively, in the untreated *Nrf2*^{-/-} mice. On APAP treatment, GCS_H and GCS_L expression was induced in wild-type mice, resulting in the *de novo* synthesis of GSH we observed in the liver. Also, the induction of GCS_H, the catalytic subunit, was much higher than that of GCS_L. In contrast, both GCS_H and GCS_L compensated poorly in *Nrf2*^{-/-} animals. GSS expression in the untreated *Nrf2*^{-/-} mice was 80% of the level in wild-type mice, and its response to APAP treatment was also blunted in the *Nrf2*^{-/-} mice. GSTpi and UGT1a6 expressions were also significantly lower in the *Nrf2*^{-/-} mice at 45 and 31%, respectively, of the

Table 2. Effect of NAC on female mice survival (%) at 48 hours with different doses of APAP

Mice	300 mg/Kg	400 mg/Kg	600 mg/Kg	800 mg/Kg
WT	100	100	12.5	0
WT + NAC	100	—	100	87.5
KO	60	0	0	0
KO + NAC	100	75	—	12.5





Fig. 4. Nrf2 gene expression after 100 and 400 mg/kg APAP injection.

wild-type baseline levels, and their response to APAP was also diminished (Fig. 3B).

To study the role Nrf2 plays in the change of expression for these enzymes, we examined the gene expression of Nrf2 in wild-type animals in response to APAP. We found that, whereas at a low dose of APAP Nrf2 was induced transiently, at a higher dose (400 mg/kg), the increase of Nrf2 was more protracted (Fig. 4). It is interesting to note that the pattern of expression for Nrf2 at 400 mg/kg APAP closely paralleled those of the enzymes described in Fig. 3B. Expression of Nrf1 was not affected by APAP in the liver of mice of either genotype (data not shown).

Pathologic Changes. To document the sequence of liver injury, we examined the liver histology in the mice of both genotypes treated with 100 and 400 mg/kg of APAP, as described above. No hepatic damage was seen at 100 mg/kg in mice of either genotype, as the drop in GSH levels was compensated for, and GSH levels were maintained. In contrast, at 90 min after 400 mg/kg APAP, overt hepatic injury was noted in the Nrf2^{-/-} mice, whereas minimal changes were seen in wild-type mice (Fig. 5). At 180 min, liver injury could be seen in mice of both genotypes. Thus histological changes preceded the rise in ALT levels, which was not observed until 270 min.

Discussion

These studies show that Nrf2 is an important component of the cellular detoxification apparatus in response to oxidative stress. Large doses of the common analgesic APAP cause liver injury by oxidative stress, and mice lacking the Nrf2 transcription factor are more susceptible to the common analgesic acetaminophen than their wild-type counterparts. Nrf2^{-/-} mice died sooner and at lower doses of APAP. For both genotypes, male mice were more sensitive than female mice to APAP. Whereas NAC, a GSH precursor used as an antidote for APAP overdose, can rescue LD₁₀₀ doses given to wild-type mice, its rescue of Nrf2^{-/-} mice is incomplete and is limited to lower APAP doses. Measurement of serum ALT activities at 24 h appears not to be a good indicator of the hepatic injury affecting the mice for several reasons. First, interanimal variability prevented statistical differentiation between the genotypes even though mortality differences were clearly observable. Second, moderate injury found on histological examination at 90 and 180 min preceded the rise in the serum ALT levels (Fig. 5).

Fig. 3. Liver GSH content and gene expression after APAP injection. Mice were injected with 100 (open symbols) or 400 mg/kg (closed symbols) APAP and killed after 90, 180, and 270 min. (A) Liver GSH expressed as micro-mol/gram of liver as a function of time after injection. (B) Gene expression calculated from Northern blots and expressed as a percentage of the level found in liver of untreated wild-type mice after normalization with glyceraldehyde-3-phosphate dehydrogenase.





Fig. 5. Liver injury found in mice at 90 min after injection of 400 mg/kg APAP. Moderate injury can be observed by the presence of cytoplasmic vacuoles in centrilobular hepatocytes in the *Nrf2*^{-/-} livers (hematoxylin/eosin). (×184.)

GSH is a molecule that plays important roles in critical physiological functions and protection against oxidative damage (25). It functions by detoxifying electrophiles and scavenging free radicals. GSH exists in high concentration in cells, and its homeostasis is maintained by a balance between the rate of synthesis and the combined rate of utilization and loss through efflux. The biosynthesis of GSH is first catalyzed by GCS and then by GSS. The rate of synthesis depends critically on the availability of GCS, a holoenzyme composed of a catalytic heavy subunit GCS_H and a regulatory light subunit GCS_L. *Nrf2*^{-/-} mice have been shown to have slight decreased basal hepatic GSH level and decreased expression of GCS_H and GCS_L (21). They can nonetheless compensate for a 57% drop in liver GSH on treatment with 100 mg/kg APAP. In contrast, the GSH level declined only 10% in the wild-type mice. We attribute this larger drop in the *Nrf2*^{-/-} mice to a deficit in the rate of GSH synthesis compared with the combined rate of utilization and efflux. At 400 mg/kg APAP, the *Nrf2*^{-/-} mice succumbed because of an inability to replenish their GSH stores (Fig. 3A).

The *Nrf2*^{-/-} mice had difficulty in detoxifying APAP and its metabolites because of the lower level of hepatic GSH. Their baseline expression of GCS_H and GCS_L was about 65 and 58% of the wild type. On challenge with 100 and 400 mg/kg of APAP, the expression of these enzymes rose only slightly. Likewise, the GSS response to APAP was also blunted in the *Nrf2*^{-/-} mice. In contrast, on APAP treatment, gene expression for both subunits was induced in wild-type mice, GCS_H induction was up more than 400%, whereas that of GCS_L was more modest at 175% the level of that of untreated mice (Fig. 3B). The lower level of expression of these enzymes that are responsible for the synthesis of GSH accounts for the less effective protection by the GSH precursor to APAP challenge in the *Nrf2*^{-/-} mice. An additional

factor that contributes to the higher sensitivity of *Nrf2*^{-/-} mice to APAP is the intrinsic lower expression of detoxifying enzymes such as UGT1a6 and GSTpi, which are important for detoxifying the toxic metabolite *N*-acetyl-*p*-benzoquinoneimine by conjugation. In the *Nrf2*^{-/-} mice, these two enzymes display a similar profile of expression to that of GCS in that their inherent expression is low, and their inductions were also lower than those observed in wild-type mice. It is interesting to note that the pattern of *Nrf2* expression on induction by APAP (Fig. 4) closely parallels those of this group of enzymes *in vivo* in the liver (Fig. 3B). This indicates that *in vivo*, *Nrf2* plays an important role in the control of the expression of these genes. In contrast, in *in vitro* experiments by using HepG2 cells line, GCS gene induction involving *Nrf2* appeared to be contingent not on increase of *Nrf2* transcript or protein (23) but on *Nrf2* release from sequestration by Keap1 (26).

These experiments showed that *Nrf2* plays a major role in the defense against APAP toxicity through the GSH synthesis pathway. It is possible that the residual GSH response in the liver of *Nrf2*^{-/-} mice is mediated by *Nrf1*, as *Nrf1*^{-/-} fibroblasts have been shown to have lower GSH levels (17). However, expression of *Nrf1* in the absence of *Nrf2* *in vivo* cannot provide adequate protection against APAP toxicity. Hence *Nrf2* must have important functions in fighting acute oxidative stress in the liver as well as previously shown in the lung (19). It remains to be seen whether lack of *Nrf2* and prolonged or chronic exposure to oxidative stress lead to DNA damage and genetic changes. If so, mutations in the *Nrf2* gene may also result in cancer predisposition.

We thank Dr. Timothy Davern for reviewing the manuscript and Dr. Jefferson Chan for helpful suggestions. The work is supported in part by National Institutes of Health Grants DK16666, DK07636, and DK50267. Y.W.K. is an Investigator of the Howard Hughes Medical Institute.

- Andrews, N. C., Erdjument-Bromage, H., Davidson, M. B., Tempst, P. & Orkin, S. H. (1993) *Nature (London)* **362**, 722–728.
- Chan, J. Y., Han, X. L. & Kan, Y. W. (1993) *Proc. Natl. Acad. Sci. USA* **90**, 11371–11375.
- Chan, J. Y., Han, X. L. & Kan, Y. W. (1993) *Proc. Natl. Acad. Sci. USA* **90**, 11366–11370.
- Moi, P., Chan, K., Asunis, I., Cao, A. & Kan, Y. W. (1994) *Proc. Natl. Acad. Sci. USA* **91**, 9926–9930.
- Caterina, J. J., Donze, D., Sun, C. W., Ciavatta, D. J. & Townes, T. M. (1994) *Nucleic Acids Res.* **22**, 2383–2391.
- Kobayashi, A., Ito, E., Toki, T., Kogame, K., Takahashi, S., Igarashi, K., Hayashi, N. & Yamamoto, M. (1999) *J. Biol. Chem.* **274**, 6443–6452.

- Oyake, T., Itoh, K., Motohashi, H., Hayashi, N., Hoshino, H., Nishizawa, M., Yamamoto, M. & Igarashi, K. (1996) *Mol. Cell. Biol.* **16**, 6083–6095.
- Tuan, D., Solomon, W., Li, Q. & London, I. M. (1985) *Proc. Natl. Acad. Sci. USA* **82**, 6384–6388.
- Forrester, W. C., Thompson, C., Elder, J. T. & Groudine, M. (1986) *Proc. Natl. Acad. Sci. USA* **83**, 1359–1363.
- Forrester, W. C., Takegawa, S., Papayannopoulou, T., Stamatoyannopoulos, G. & Groudine, M. (1987) *Nucleic Acids Res.* **15**, 10159–10177.
- Rushmore, T. H., Morton, M. R. & Pickett, C. B. (1991) *J. Biol. Chem.* **266**, 11632–11639.
- Prester, T., Holtzclaw, W. D., Zhang, Y. & Talalay, P. (1993) *Proc. Natl. Acad. Sci. USA* **90**, 2965–2969.

13. Xie, T., Belinsky, M., Xu, Y. & Jaiswal, A. K. (1995) *J. Biol. Chem.* **270**, 6894–6900.
14. Wasserman, W. W. & Fahl, W. E. (1997) *Proc. Natl. Acad. Sci. USA* **94**, 5361–5366.
15. Venugopal, R. & Jaiswal, A. K. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 14960–14965.
16. Venugopal, R. & Jaiswal, A. K. (1998) *Oncogene* **17**, 3145–3156.
17. Kwong, M., Kan, Y. W. & Chan, J. Y. (1999) *J. Biol. Chem.* **274**, 37491–37498.
18. Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., *et al.* (1997) *Biochem. Biophys. Res. Commun.* **236**, 313–322.
19. Chan, K. & Kan, Y. W. (1999) *Proc. Natl. Acad. Sci. USA* **96**, 12731–12736.
20. Alam, J., Stewart, D., Touchard, C., Boinapally, S., Choi, A. M. & Cook, J. L. (1999) *J. Biol. Chem.* **274**, 26071–26078.
21. Chan, J. Y. & Kwong, M. (2000) *Biochim. Biophys. Acta* **1517**, 19–26.
22. Moinova, H. R. & Mulcahy, R. T. (1999) *Biochem. Biophys. Res. Commun.* **261**, 661–668.
23. Wild, A. C., Moinova, H. R. & Mulcahy, R. T. (1999) *J. Biol. Chem.* **274**, 33627–33636.
24. Cohen, S. D., Hoivik, D. J. & Khairallah, E. A. (1998) in *Toxicology of the Liver*, eds. Plaa, G. L. & Hewitt, W. R. (Taylor & Francis, Bristol, PA), Vol. 1, pp. 159–186.
25. Lu, S. C. (1999) *FASEB J.* **13**, 1169–1183.
26. Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D. & Yamamoto, M. (1999) *Genes Dev.* **13**, 76–86.